Longview Partners Guernsey LTD lowered its stake in Mednax, Inc (NYSE:MD) by 50.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,491,731 shares of the company’s stock after selling 2,531,745 shares during the period. Mednax accounts for 0.6% of Longview Partners Guernsey LTD’s holdings, making the stock its 24th largest holding. Longview Partners Guernsey LTD owned approximately 2.66% of Mednax worth $107,443,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently modified their holdings of MD. JPMorgan Chase & Co. boosted its position in Mednax by 55.2% in the first quarter. JPMorgan Chase & Co. now owns 79,610 shares of the company’s stock valued at $5,524,000 after buying an additional 28,301 shares in the last quarter. OppenheimerFunds Inc. boosted its position in Mednax by 14.5% in the first quarter. OppenheimerFunds Inc. now owns 11,379 shares of the company’s stock valued at $789,000 after buying an additional 1,439 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Mednax by 0.5% in the first quarter. PNC Financial Services Group Inc. now owns 9,099 shares of the company’s stock valued at $632,000 after buying an additional 47 shares in the last quarter. Thrivent Financial For Lutherans boosted its position in Mednax by 12.5% in the first quarter. Thrivent Financial For Lutherans now owns 17,760 shares of the company’s stock valued at $1,232,000 after buying an additional 1,980 shares in the last quarter. Finally, Morgan Stanley boosted its position in Mednax by 78.3% in the first quarter. Morgan Stanley now owns 361,509 shares of the company’s stock valued at $25,082,000 after buying an additional 158,720 shares in the last quarter. Hedge funds and other institutional investors own 99.97% of the company’s stock.
A number of analysts have weighed in on the stock. BMO Capital Markets assumed coverage on shares of Mednax in a research report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price on the stock. Zacks Investment Research upgraded shares of Mednax from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Jefferies Group LLC restated a “hold” rating and issued a $46.00 target price on shares of Mednax in a research report on Tuesday, October 3rd. KeyCorp upgraded shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price on the stock in a research report on Sunday, September 17th. Finally, Robert W. Baird restated a “hold” rating and issued a $47.00 target price on shares of Mednax in a research report on Sunday, September 3rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company’s stock. Mednax presently has an average rating of “Hold” and an average price target of $55.44.
ILLEGAL ACTIVITY WARNING: “Mednax, Inc (MD) Shares Sold by Longview Partners Guernsey LTD” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://sportsperspectives.com/2017/11/01/mednax-inc-md-shares-sold-by-longview-partners-guernsey-ltd.html.
Shares of Mednax, Inc (MD) traded down 4.64% during trading on Wednesday, hitting $41.76. 1,999,664 shares of the stock were exchanged. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of 13.30 and a beta of 0.37. The stock’s 50 day moving average price is $43.19 and its 200 day moving average price is $50.86. Mednax, Inc has a 52 week low of $40.78 and a 52 week high of $72.13.
Mednax (NYSE:MD) last issued its quarterly earnings results on Wednesday, October 25th. The company reported $0.87 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.87. The firm had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.09 EPS. On average, equities analysts predict that Mednax, Inc will post $3.30 earnings per share for the current year.
In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the sale, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by corporate insiders.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.